Dyno Therapeutics to Present Cutting-Edge AAV Gene Delivery Data for CNS, Eye, and Muscle at 2025 ASGCT Annual Meeting Dyno Therapeutics, Inc., a pioneer in genetic technologies harnessing the power…
Obsidian Therapeutics to Present Groundbreaking Preclinical Data on cytoDRiVE® Platform at the 2025 ASGCT Annual Meeting Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to cell and gene…
Sangamo Therapeutics to Highlight Neurology Pipeline Innovations with Nine Presentations at 28th ASGCT Annual Meeting Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company focused on developing transformative therapies for…
Strand Therapeutics Unveils Groundbreaking Preclinical Data for STX-003, a Programmable mRNA Therapy Targeting Solid Tumors Strand Therapeutics Inc., a biotechnology company pioneering programmable mRNA technology to develop curative therapies for…
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company committed to developing transformative genetic medicines for patients and families affected by rare neurological diseases, has announced its upcoming participation in the…
Personalis’ NeXT Personal® Demonstrates 100% Early Detection of Colorectal Cancer Relapses Ahead of Imaging in Interim VICTORI Study Results Presented at the 2025 Annual Meeting of the American Association for…
Affinia Therapeutics to Present Breakthrough Data on AFTX-201, Novel BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Advancements at ASGCT 2025 Affinia Therapeutics, a pioneering gene therapy company focused on developing potentially…
Pfizer’s Sasanlimab Combination Significantly Extends Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer Patients Pfizer Inc. (NYSE: PFE) today announced encouraging results from the pivotal Phase 3 CREST trial,…
UroGen Pharma Announces Promising Early Results from Phase 1 Study Evaluating UGN-301 for Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company committed to developing and commercializing…
eClinicalWorks & Sunoh.ai: Deeper Patient Interactions in Behavioral Health Health Opportunities for the People of East Texas (HOPE), a leading Federally Qualified Health Center (FQHC), has successfully implemented Sunoh.ai, an…
PCI Pharma to Acquire Ajinomoto Althea PCI Pharma Services (PCI), a global leader in contract development and manufacturing (CDMO) focused on biopharmaceutical innovation, has announced the acquisition of Ajinomoto Althea,…
Ivonescimab + Chemo Outperforms PD-1 Combo in 1L Squamous NSCLC in Akeso’s HARMONi-6 Study Summit Therapeutics Inc. (NASDAQ: SMMT) has announced that Akeso, Inc. (HKEX: 9926.HK) has successfully met the…